Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Open Access
- 10 August 2022
- journal article
- review article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 37 (5), 906-919
- https://doi.org/10.3904/kjim.2022.152
Abstract
The incidence and prevalence of inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, have increased in Asia and developing countries. In the past two decades, anti-tumor necrosis factor (TNF) agents have revolutionized the treatment of IBD, in part by decreasing the rates of complications and surgery. Although anti-TNF agents have changed the course of IBD, there are unmet needs in terms of primary and secondary non-responses and side effects such as infections and malignancies. Novel biologics and small-molecule drugs have been developed for IBD, and the medical treatment options have improved. These drugs include sphingosine-1-phosphate receptor modulators and anti-integrins to block immune cell migration, and cytokine and Janus kinase inhibitors to block immune cell communications. In this review, we discuss the approved novel biologics and small-molecule drugs, including several of those in the late stages of development, for the treatment of IBD.This publication has 95 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2013
- Discovery and mechanism of ustekinumabmAbs, 2011
- Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptorsNature Chemical Biology, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE TrialGastroenterology, 2007
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabThe New England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisThe New England Journal of Medicine, 2005
- Structural and functional characteristics of S1P receptorsJournal of Cellular Biochemistry, 2004
- Regulation of JAK–STAT signalling in the immune systemNature Reviews Immunology, 2003